Albumin fusion proteins

• US 7,521,424 B2
• Filed: 07/07/2005
• Issued: 04/21/2009
• Est. Priority Date: 01/22/2003
• Status: Expired due to Term

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Rosen, Craig A., Haseltine, William A., Ruben, Steven M.
• Primary Examiner(s): Monshipouri; Maryam
• Assistant Examiner(s): Tsay; Marsha M
• Application Number:
  US11/175,690
• Publication Number:
  US 20060014254A1
• Time in Patent Office: 1,384 Days
• Field of Search: 424/192.1, 514/12, 435/69.7
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 47/643 Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
• CPC Class Codes: C07K 14/765 Serum albumin, e.g. HSA
• CPC Class Codes: C07K 2319/31 fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Claims

1. A method of treating memory loss in a patient, comprising administering to said patient an albumin fusion protein comprising two or more tandemly oriented glucagon-like peptide-1 (GLP-1) polypeptides, wherein (i) said GLP-1 polypeptides are selected from wild-type GLP-1, GLP-1 fragments, and GLP-1 variants, fused to albumin comprising the amino acid sequence of SEQ ID NO:

1, fragment or variant thereof, (ii) said albumin fusion protein has an increased serum plasma half-life compared with GLP-1 that is not fused to said albumin or a fragment or variant thereof, and (iii) said albumin fusion protein has GLP-1 activity.

2. The method of claim 1, wherein said tandemly oriented GLP-1 polypeptides are selected from wild type GLP-1 sequences.

3. The method of claim 1, wherein said tandemly oriented GLP-1 polypeptides are selected from GLP-1 fragment sequences.

4. The method of claim 1, wherein said tandemly oriented GLP-1 polypeptides are selected from GLP-1 variant sequences.

5. The method of claim 1, wherein said GLP-1 fragments or GLP-1 variants are selected from two tandemly oriented GLP-1(7-36(A8G)).

6. The method of claim 5, wherein said two tandemly oriented GLP-1(7-36(A8G)) are fused at the N-terminus to albumin.

7. The method of claim 5, wherein said two tandemly oriented GLP-1(7-36(A8G)) are fused at the C-terminus to albumin.

8. The method of claim 1, wherein said albumin fusion protein is produced from a host cell comprising a construct which expresses said albumin fusion protein, and wherein said construct is selected from:

a) 3430

b) 3438, and

c) 3070.

9. The method of claim 1, comprising administering an albumin fusion protein comprising two or more tandemly oriented GLP-1 polypeptides fused to albumin, wherein said fusion protein is produced from a host cell comprising the amino acid sequence of the 3070 construct contained in ATCC Deposit No. PTA-4671.

10. A method of treating memory loss in a patient, comprising administering to said patient an albumin fusion protein comprising a single copy of GLP-1(7-36(A8G)), fused to albumin comprising the amino acid sequence of SEQ ID NO:

1, fragment or variant thereof, (ii) said albumin fusion protein has an increased serum plasma half life compared with GLP-1 that is not fused to said albumin or a fragment or variant thereof, and (iii) said albumin fusion protein has GLP-1 activity.

11. The method of claim 10 , wherein said GLP-1(7-36(A8G)) is fused at the N-terminus to albumin.

12. The method of claim 10 , wherein said GLP-1(7-36(A8G)) is fused at the C-terminus to albumin.

13. The method of claim 10, wherein said albumin fusion protein is produced from a host cell comprising a construct which expresses said albumin fusion protein, and wherein said construct is selected from:

a) 3446

b) 3447

c) 3458

d) 3459

e) 3460

f) 3461

g) 3462

h) 3479

i) 3480

j) 3481

k) 3482

l) 3493

m) 3494 and

n) 3495.

14. The method of claim 10, wherein said albumin fusion protein comprises an amino acid sequence selected from:

a) amino acids 30 to 650 of SEQ ID NO;

209;

b) amino acids 30 to 650 of SEQ ID NO;

210;

c) amino acids 30 to 647 of SEQ ID NO;

212;

d) amino acids 30 to 649 of SEQ ID NO;

213;

e) amino acids 30 to 648 of SEQ ID NO;

214;

f) amino acids 30 to 653 of SEQ ID NO;

215;

g) amino acids 30 to 657 of SEQ ID NO;

216;

h) amino acids 30 to 652 of SEQ ID NO;

218;

i) amino acids 30 to 654 of SEQ ID NO;

219;

j) amino acids 30 to 655 of SEQ ID NO;

220;

k) amino acids 30 to 659 of SEQ ID NO;

221;

l) amino acids 30 to 646 of SEQ ID NO;

223;

m) amino acids 30 to 651 of SEQ ID NO;

224; and

n) amino acids 30 to 656 of SEQ ID NO;

225.